An immunohistochemical study of the dermal infiltrate and epidermal staining for interleukin 1 in 12 cases of Sweet's syndrome

British Journal of Dermatology

Volumn 134, Issue 4, 1996, Pages 705-709

  Bourke, J F ^a   Jones, J L ^a   Fletcher, A ^a   Graham Brown, R A C ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 12;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; SKIN INFLAMMATION;

EID: 0029875935     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1996.tb06975.x     Document Type: Article

References (10)

1. Jordaan HF. Acute febrile neutrophilic dermatosis - a histopathological study of 37 patients and a review of the literature. Am J Dermatopathol 1989; 11: 99-111.
2. Alvaro T, Garcia del Moral R, Gomez-Morales M et al. Immunopathological studies of Sweet's syndrome responding to cyclosporin. Br J Dermatol 1991; 124: 111-12.
3. Bourke JF, Berth-Jones J, Graham-Brown RAC. Sweet's syndrome responding to cyclosporin. Br J Dermatol 1992; 127: 36-8.
4. Sharpe GR, Leggat HM. A case of Sweet's syndrome and myelodysplasia: response to cyclosporin. Br J Dermatol 1992; 127: 538-9.
5. Delabie J, De Wolf-Peeters C, Morren M et al. Histiocytes in Sweet's syndrome. Br J Dermatol 1991; 124: 348-53.
6. Going JJ. Is the pathogenesis of Sweet's syndrome mediated by interleukin 1? Br J Dermatol 1987; 116: 282-3.
7. Nozaki S, Feliciani C, Sauder DN. Keratinocyte cytokines. In: Advances in Dermatology (Callen JP, Dahl MV, Goltz LE et al., eds), Vol. 7. Chicago: Mosby Yearbook, 1992; 83-101.
8. Dinarello CA. Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med 1984; 311: 1413-8.
9. Park JW, Mehrotra B, Barnett BO et al. The Sweet syndrome during treatment with granulocyte colony-stimulating factor. Ann Intern Med 1992; 116: 996-8.
10. Horn TD, Burke PJ, Karp JE et al. Intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor causes a cutaneous eruption. Arch Dermatol 1991; 127: 49-52.